A reduced number and/or reduced activity of natural killer (NK) cells, which are important for defense against a variety of cancers and viral infections, occur under various stress conditions and in patients with various diseases. In this article, we report that the 30% to 50% ethanol precipitate of oyster extract (EPOE50) dose-dependently enhanced the activity of mouse spleen NK cells in vitro and in vivo. The activity of EPOE50 was eluted with a molecular weight of about 2000 by gel filtration and was inactivated by periodate but not by proteinase K. The activity of highly purified NK cells was also augmented by EPOE50 but not by oligodeoxyribonucleotide 1585, which mimics bacterial DNA. Administration of EPOE50 to mice stimulated splenic NK cell activity without a change in splenic NK cell populations. Although the proliferation of B16 tumor cells in vitro was slightly stimulated by EPOE50, the growth of B16 melanoma in vivo was dose-dependently suppressed by administration of EPOE50. Taken together, our results indicate that EPOE50 augmented NK cell activity and that its administration to mice inhibited tumor growth presumably through the activation of NK cells and also suggest that the active substance is a sugar-containing oligomer or polymer and is not of bacterial origin.
A reduced number and/or reduced activity of natural killer (NK) cells, which are important for defense against a variety of cancers and viral infections, occur under various stress conditions and in patients with various diseases. In this article, we report that the 30% to 50% ethanol precipitate of oyster extract (EPOE50) dose-dependently enhanced the activity of mouse spleen NK cells in vitro and in vivo. The activity of EPOE50 was eluted with a molecular weight of about 2000 by gel filtration and was inactivated by periodate but not by proteinase K. The activity of highly purified NK cells was also augmented by EPOE50 but not by oligodeoxyribonucleotide 1585, which mimics bacterial DNA. Administration of EPOE50 to mice stimulated splenic NK cell activity without a change in splenic NK cell populations. Although the proliferation of B16 tumor cells in vitro was slightly stimulated by EPOE50, the growth of B16 melanoma in vivo was dose-dependently suppressed by administration of EPOE50. Taken together, our results indicate that EPOE50 augmented NK cell activity and that its administration to mice inhibited tumor growth presumably through the activation of NK cells and also suggest that the active substance is a sugar-containing oligomer or polymer and is not of bacterial origin.
Entities:
Keywords:
NK cell; activation; antitumor effect; melanoma; oyster
Natural killer (NK) cells are part of the innate immune system and are important for
defense against a variety of cancers and viral, bacterial, and parasitic
infections.[1-3] Evidence for
important roles in immunity has been provided by animal models as well as patients
deficient in NK cells.[4] NK cells rapidly kill target cells without prior immunization or major
histocompatibility complex restriction while leaving normal healthy cells unharmed.
Their activation is regulated by a complex balance of activating and inhibitory
signals. These signals are transmitted by activating receptors that bind ligands on
tumors and pathogen-infected cells and by inhibitory receptors that bind class I
major histocompatibility complex molecules.[1,5] The latter receptors, which are
dominant and prevent NK cell activation, explain self-tolerance and prevention of
host cell killing. Other than surface receptors, cytokines, including interleukin
(IL)-2, IL-12, IL-15, IL-18, and IL-21, have been shown to play a crucial role in
activating NK cells and enhancing NK cytotoxicity against a tumor.[1,6]Reduced NK cell number and/or reduced activity have been found to occur under various
stress conditions and in patients with cancer, viral infection, chronic
inflammation, and chronic fatigue syndrome.[7-10] It is also known that some
chemotherapy drugs and radiation therapy have side effects including suppression of
NK cell activity.[11-14] Such reduction removes the
protective function of NK cells and would result in increased pathogenic viral
infections and even cancer. Thus, it is important to restore the activity of NK
cells for people who have low NK cell activity.IL-2 has been the most commonly used cytokine for clinical trials to enhance the
antitumor potential of NK cells. Systemic administration of IL-2 is now approved by
the US Food and Drug Administration for use in malignant melanoma and metastatic
renal cell carcinoma.[15] However, since IL-2 perturbs complex regulatory pathways, serious side
effects, including vascular leak syndrome, have been observed.[15] Moreover, IL-2 also has a critical role in the generation and maintenance of
regulatory T cells, which act to suppress a variety of immune responses.[16] There is an obvious need for more specific NK cell modulators that lack
wide-ranging side effects.Foods have the advantage of being safe and easy to take. Some foods and their
components have been reported to enhance NK cell activity. They include
water-soluble extracts of Agaricus blazei Murill mushrooms, the
lactic acid bacterium Lactobacillus plantarumHY7712, nucleotides,
and vitamin E.[17-21] We have investigated NK
cell-stimulating activity in crude extracts of foods, especially vegetables and
marine products. During our investigation using murine spleen cells in vitro, we
found that an extract of oysters enhanced the cytotoxicity of NK cells. In this
article, we show that the ethanol precipitate prepared from the extract of oysters
potently augmented NK cell activity in spleen cells both in vitro and in vivo. We
also describe the in vivo antitumor effect of the ethanol precipitate.
Materials and Methods
Reagents
RPMI-1640 medium, Phenol Red-free RPMI-1640 medium, propidium iodide, and
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (MTT) were obtained from Sigma-Aldrich, Inc (St Louis, MO). Calcein
acetoxymethyl ester (calcein-AM) was purchased from Dojindo Laboratories
(Kumamoto, Japan). Recombinant mouseIL-2 was obtained from Roche Applied
Science (Indianapolis, IN). Oligodeoxynucleotide (ODN) 1585 and its negative
control were purchased from InvivoGen (San Diego, CA). Mouse NK cell separation
set-DM, mouse NK cell enrichment set-DM, and phycoerythrin (PE)-conjugated rat
anti-mouseNK1.1, fluorescein isothiocyanate (FITC)-conjugated hamster
anti-mouseCD3 ϵ chain, and rat anti-mouseCD16/CD32 monoclonal antibodies
(mAbs) were obtained from BD Biosciences (San Jose, CA).
Preparation of Oyster Extracts and Ethanol Fractionation
One- or 2-year-old oysters, Crassostrea gigas, were obtained
from a hanging culture bed in Seto Inland Sea of Hiroshima Prefecture and
Okayama Prefecture, Japan. They were extracted with 1.5 volumes of water for 1.5
hours at 125°C and 2364 hPa, and the mixture was filtered. The filtrate was
concentrated, sterilized, and spray-dried. The resulting powder (oyster extract
[OE]) was dissolved in water and fractionated by graded precipitation at ethanol
concentrations of 30% and 50% (v/v). The 50% ethanol supernatant was evaporated
to dryness under reduced pressure. The 30% and 50% ethanol precipitates and the
residue of 50% ethanol supernatant were then lyophilized, and the resulting
powders were stored at 4°C. The powder weight percentages of the 30% ethanol
precipitate, 50% ethanol precipitate, and 50% ethanol supernatant were 5.3 ±
0.3%, 2.6 ± 0.5%, and 92.1 ± 0.8%, respectively (mean ± SEM for 3 independent
experiments). Since most of the NK cell-enhancing activity was retained in the
50% ethanol precipitate as described in the Results section (Figure 1A), the 50%
ethanol precipitate, which is referred to as EPOE50, was used thereafter.
Figure 1.
Enhancement of NK cell cytolytic activity in vitro by 30% to 50% ethanol
precipitate of oyster extract (EPOE50). Spleen cells were incubated for
48 hours (A) and for 24 and 48 hours (B) with or without 1 mg/mL of
oyster extract (OE) (A), 1 mg/mL of ethanol fractions a-c (A), indicated
doses of EPOE50 (B), or 5 ng/mL of IL-2 (A and B). Fraction a, 30%
ethanol precipitate of OE; Fraction b, 50% ethanol precipitate of OE;
Fraction c, 50% ethanol supernatant of OE. The NK cell cytotoxic
activity against YAC-1 tumor cells was then determined. The data are
means ± SEM of 3 independent experiments. *P < .05,
**P < .01, and ***P < .001,
as compared with the values of respective control cultures incubated in
the medium alone.
Enhancement of NK cell cytolytic activity in vitro by 30% to 50% ethanol
precipitate of oyster extract (EPOE50). Spleen cells were incubated for
48 hours (A) and for 24 and 48 hours (B) with or without 1 mg/mL of
oyster extract (OE) (A), 1 mg/mL of ethanol fractions a-c (A), indicated
doses of EPOE50 (B), or 5 ng/mL of IL-2 (A and B). Fraction a, 30%
ethanol precipitate of OE; Fraction b, 50% ethanol precipitate of OE;
Fraction c, 50% ethanol supernatant of OE. The NK cell cytotoxic
activity against YAC-1tumor cells was then determined. The data are
means ± SEM of 3 independent experiments. *P < .05,
**P < .01, and ***P < .001,
as compared with the values of respective control cultures incubated in
the medium alone.
Mice
Female C57BL/6N mice, purchased from Charles River Japan (Yokohama, Japan) and
Shandong University Laboratory Animal Center (Jinan, China), were maintained
under specific pathogen-free conditions in the animal facilities of Okayama
University (Okayama, Japan) and Jining Medical College (Rizhao, China) and were
used between 7 and 12 weeks of age. Mouse experiments were conducted according
to the Policy on the Care and Use of the Laboratory Animals, Okayama University,
under protocols approved by the Animal Care and Use Committee, Okayama
University.
Determination of OE Chemical Composition
The nitrogen content was determined by the Kjeldahl method[22] and was multiplied by a factor of 6.25 to calculate the protein content.
The glycogen content was determined by the Somogyi method after trichloroacetic
acid extraction, ethanol precipitation, and hydrochloric acid hydrolysis.[23] Taurine was measured as described previously.[24] Direct dry ashing was done as described previously.[25] The zinc content was determined with Hitachi Z-5000 atomic absorption
spectrophotometer (Tokyo, Japan) at wavelength of 213.8 nm using air-acetylene
flame after direct dry ashing.
Preparation of Erythrocyte-Depleted Spleen Cells and Highly Purified NK
Cells
Erythrocyte-depleted murine spleen cells were prepared from whole spleen cells by
lysis of erythrocytes with ACK lysis buffer (0.15 M NH4Cl, 10 mM
KHCO3, and 0.1 mM Na2EDTA, pH 7.2) and hereinafter are
referred to as spleen cells. Highly purified NK cells were prepared from the
spleen cells by negative selection using a mouse NK cell enrichment set-DM plus
positive selection using a mouse NK cell separation set-DM according to the
manufacturer’s protocol. The purity of recovered viable NK cells was more than
96% when the cells were stained with PE-conjugated anti-mouseNK1.1 mAb,
FITC-conjugated anti-mouseCD3 ϵ chain mAb, and propidium iodide after
preincubation of the cells with anti-mouseCD16/CD32 mAb and then analyzed by a
flow cytometer (BD FACSCalibur, BD Biosciences) as described previously.[26]
NK Cell-Enhancing Activity
Spleen cells (1 × 106 cells/200 µL/well) or highly purified NK cells
(1 × 105 cells/200 µL/well) were incubated for 48 hours, unless
otherwise specified, with or without EPOE50 and other agents in a basal medium
(Phenol Red-free RPMI 1640 medium supplemented with 10% heat-inactivated fetal
calf serum [FCS], 2 mM L-glutamine, 100 U/mL of penicillin G, and 100 µg/mL of
streptomycin) containing 50 µM 2-mercaptoethanol at 37°C in an atmosphere
containing 5% CO2 in triplicate in 96-well flat-bottom plates (Nunc,
Roskilde, Denmark). The cells in each plate were then washed once with the basal
medium lacking FCS, and the cytotoxic activity of NK cells was determined as
described in the next section.
Cytotoxic Activity of NK Cells
The cytotoxic activity of NK cells was assayed as described previously.[26] Briefly, YAC-1 cells (106/mL of the basal medium), obtained
from Riken BioResource Center Cell Bank (Tsukuba, Japan), were pre-incubated
with 15 µM calcein AM for 30 minutes at 37°C with occasional shaking and washed
twice with the basal medium lacking FCS. The spleen cells or highly purified NK
cells (effector cells), which had been pre-stimulated and washed as described in
the previous section, or spleen cells (1 × 106 cells/well) from mice
treated with EPOE50 or PBS were incubated for 4 hours with the YAC-1 cells
(target cells, 2 × 104 cells) at an E:T ratio of 50:1 for spleen
cells or with the YAC-1 cells (1 × 104 cells) at an E:T ratio of 10:1
for highly purified NK cells in triplicate in 200 µL/well of the basal medium.
The plate containing cells was then centrifuged and washed twice with the basal
medium lacking FCS. The plate was blotted dry, and 200 µL of 1% Triton X-100 in
25 mM borate buffer (pH 9.0) was added to each well. Fluorescence of individual
wells was measured with a microplate fluorometer. The wavelengths of the filters
used were excitation at 485 nm and emission at 527 nm. The percentage of
cytotoxic activity was calculated as follows: cytotoxic activity (%) = (average
fluorescence in wells incubated with target cells alone − fluorescence in wells
of the experimental group)/(average fluorescence in wells incubated with target
cells alone − average fluorescence in wells incubated with effector cells alone)
× 100.
NK Cell Activity After Administration of EPOE50 In Vivo
Mice were intraperitoneally injected with phosphate-buffered saline (PBS) or
EPOE50 dissolved in PBS (100, 200, and 300 mg/kg) for 3 consecutive days. Spleen
cells (1 × 106 cells/200 µL/well) prepared from those mice 2 hours
after the last injection were incubated with the target cells for the assay of
cytotoxic activity of NK cells.
Flow Cytometric Analysis of NK Cells
NK cell populations in spleen cells were analyzed by flow cytometry as described previously.[26] Briefly, spleen cells, prepared from mice treated with EPOE50 or PBS,
were washed with and suspended in PBS containing 0.5% bovine serum albumin and
0.1% sodium azide (~1 × 106 cells/100 µL). The cells were then
incubated with anti-mouseCD16/CD32 mAb (10 µg/mL) for 5 minutes on ice and
stained with PE-conjugated rat anti-mouseNK1.1 mAb (4 µg/mL) plus
FITC-conjugated anti-mouseCD3ϵ mAb (10 µg/mL) for 30 minutes on ice. After
being washed with and suspended in PBS containing 0.5% bovine serum albumin and
0.1% sodium azide, the cells were stained with propidium iodide (2 µg/mL), and
expression of NK 1.1 and CD3ϵ on viable cells was analyzed by a flow cytometer
(Epics XL, Beckman Coulter). NK1.1+CD3ϵ− cells were
regarded as NK cells.
Gel Filtration of EPOE50
EPOE50 dissolved in PBS (20 mg/mL, 2 mL) was applied to a column of Sephadex G-25
(1.45 × 5 cm) equilibrated with PBS and eluted with the same buffer at 4°C.
Fractions of 1 mL were collected, and aliquots (50 µL) of each fraction were
subjected to the assay of NK cell-enhancing activity with spleen cells.
Treatment of EPOE50 With Sodium Periodate
EPOE50 (50 mg/2.5 mL of PBS) was incubated with or without 40 mM sodium periodate
for 48 hours at 4°C. After addition of 0.54 M sodium thiosulfate in 200 µL of
PBS, 2 mL of the reaction mixture was applied to a column of Sephadex G-25 (1.45
× 5 cm) equilibrated with PBS and eluted with the same buffer. Fractions of 1 mL
were collected, and aliquots (50 µL) of eluted fractions were subjected to the
assay of NK cell-enhancing activity with spleen cells.
Treatment of EPOE50 With Proteinase K
EPOE50 (1.5 or 3 mg/mL of PBS) or PBS was incubated with or without proteinase K
(0.25 mg/mL of PBS) for 30 minutes at room temperature. The reaction was stopped
by heating the mixture for 15 minutes at 90°C. Aliquots (50 µL) of reaction
mixtures were subjected to the assay of NK cell-enhancing activity with spleen
cells.
Antitumor Activity of EPOE50 In Vivo
B16 melanoma cells (5 × 105 cells) obtained from Riken BioResource
Center Cell Bank were subcutaneously inoculated into the lower back of each
C57BL/6 mouse. PBS or EPOE50 dissolved in PBS was intraperitoneally (100, 200,
and 300 mg/kg) or orally (2 g/kg) administered to mice once a day for 17 days
starting 3 days before tumor inoculation. The lengths of major and minor axes of
the tumors were measured, and the tumor volume was calculated by using the
following formula: (length of minor axes)[2] × (length of major axes)/2.[27]
Antitumor Activity of EPOE50 In Vitro
B16 melanoma cells (1 × 103 cells/150 µL/well) were pre-incubated for
24 hours in RPMI 1640 medium, supplemented with 10% heat-inactivated FCS, 2 mM
L-glutamine, 100 U/mL penicillin G, and 100 µg/mL streptomycin, at 37°C in an
atmosphere containing 5% CO2 in triplicate in 96-well flat-bottom
plates (Nunc). Fifty microliters of the same fresh medium containing or not
containing EPOE50 was added to wells, and the cultures were further incubated
for 48 hours. After centrifugation of the plate, portions (160 µL) of the
culture supernatant were removed. To each well of the plate, the same fresh
medium (60 µL) was added, and MTT assay of viable cells was performed as
described previously except that the incubation time with MTT was 2 hours.[28]
Statistical Analysis
Results are expressed as means and SEMs of 3 independent experiments or 5 to 9mice. Data in 2 groups were analyzed by Student’s t test.
Multiple comparison of the data was done by ANOVA followed by Tukey’s test.
P values less than .05 were regarded as significant.
Results
Chemical Composition of OE
The contents of protein (%), glycogen (%), taurine (%), zinc (ppm), ash (%), and
moisture (%) in OE were 33.6 ± 1.4, 26.5 ± 1.3, 5.4 ± 0.1, 330 ± 6, 12.9 ± 0.6,
and 3.7 ± 0.2 (n = 3), respectively.
Augmentation of NK Cell Activity In Vitro by EPOE50
Spleen cells including NK cells were incubated in vitro for 48 hours with OE,
graded ethanol precipitates, and the residue of 50% ethanol supernatant, and NK
cell activity was then determined. Most of the NK cell-enhancing activity was
retained in the 50% ethanol precipitate (fraction b), the activities of the 30%
ethanol precipitate (fraction a), and the 50% ethanol supernatant (fraction c)
being minimal (Figure
1A). Therefore, the 50% ethanol precipitate, referred to as EPOE50, was
used in the subsequent experiments. NK cell activity was augmented in a
dose-dependent manner by 0.375 to 1.5 mg/mL of EPOE50, the enhancement after
48-hour exposure being greater than that after 24-hour exposure (Figure 1B).
Forty-eight-hour exposure to 1.5 mg/mL of EPOE50 resulted in a 10-fold increase
in NK cell activity, which was as marked as the effect of 5 ng/mL of IL-2 (Figure 1B).
Enhancement of NK Cell Activity In Vivo by EPOE50
In order to examine the in vivo effect of EPOE50 on NK activity, mice were
intraperitoneally administered the ethanol precipitate (100, 200, and 300 mg/kg)
for 3 consecutive days, and NK activities of their spleen cells were determined.
The splenic NK activity in mice treated with EPOE50 markedly increased in a
dose-dependent manner (Figure
2A). In contrast, splenic NK cell populations did not significantly
change in the mice treated with either dose of the ethanol precipitate, as
determined by flow cytometry (Figure 2B).
Figure 2.
Enhancement of murine NK cell cytolytic activity in vivo by EPOE50. Mice
were intraperitoneally injected with EPOE50 (100, 200, and 300 mg/kg) in
0.2 mL/head of PBS or PBS alone (control) for 3 consecutive days. NK
cell cytotoxic activity of spleen cells prepared from those mice against
YAC-1 tumor cells was then determined (A). Spleen cells were also
stained with PE-conjugated NK1.1 mAb and FITC-conjugated CD3ϵ mAb and
analyzed by a flow cytometer. The percentage of
NK1.1+CD3ϵ− NK cell populations is shown (B).
The data are means ± SEM of 9 mice. a-dDifferent superscript
letters indicate significant difference (P < .05,
P < .01, or P < .001).
Enhancement of murine NK cell cytolytic activity in vivo by EPOE50. Mice
were intraperitoneally injected with EPOE50 (100, 200, and 300 mg/kg) in
0.2 mL/head of PBS or PBS alone (control) for 3 consecutive days. NK
cell cytotoxic activity of spleen cells prepared from those mice against
YAC-1tumor cells was then determined (A). Spleen cells were also
stained with PE-conjugated NK1.1 mAb and FITC-conjugated CD3ϵ mAb and
analyzed by a flow cytometer. The percentage of
NK1.1+CD3ϵ− NK cell populations is shown (B).
The data are means ± SEM of 9 mice. a-dDifferent superscript
letters indicate significant difference (P < .05,
P < .01, or P < .001).
Properties of an Active Substance in EPOE50
EPOE50 was subjected to gel filtration to determine the molecular weight of a
substance with NK cell-enhancing activity. The active substance(s) was eluted in
a peak with apparent molecular weight of about 2000 (Figure 3A). To test the chemical property
of active substance(s), EPOE50 was treated with sodium periodate and proteinase
K. Sodium periodate opens saccharide rings between vicinal diols leaving 2
aldehyde groups.[29] After incubation of EPOE50 with or without sodium periodate, excess
sodium periodate was inactivated by addition of the reducing agent sodium
thiosulfate and removed by gel filtration. Enhancement of NK cell activity by
eluted fractions was then assayed. The activity in fractions 2 to 4 of
periodate-treated EPOE50 was reduced to the level of basal NK activity (Figure 3B). In contrast,
enhancement of NK activity of EPOE50 was not influenced by treatment with
proteinase K (Figure
3C).
Figure 3.
Properties of an active substance with a NK cell-enhancing activity in
EPOE50. (A) Gel filtration profile of the NK cell-enhancing activity.
Two milliliters of EPOE50 (20 mg/mL) was applied to a Sephadex G-25
column, and 1-mL fractions were collected. Aliquots (50 µL) of each
fraction were subjected to the assay of NK cell-enhancing activity using
spleen cells. Molecular weight markers used were insulin A chain (2531),
bacitracin (1423), and NaCl (58.4). The data are representative of 3
independent experiments with similar results and expressed as means ±
SEM of triplicate cultures. (B) Inactivation of the NK cell-enhancing
activity in EPOE50 treated with periodate. After being incubated with or
without periodate and subsequent removal of periodate by gel filtration
of the reaction mixture, aliquots (50 µL) of each eluted fraction were
subjected to the assay of NK cell-enhancing activity using spleen cells.
Cytotoxicity of spleen cells alone was 7.1 ± 1.8%. The data are means ±
SEM of 3 independent experiments. **P < .01, and
***P < .001, as compared with the values of
control cultures incubated with the eluates of untreated EPOE50. (C) The
NK cell-enhancing activity in EPOE50 is resistant to proteinase K
treatment. After being incubated with or without proteinase K and
subsequent heating, aliquots (50 µL) of each reaction mixture were
subjected to the assay of NK cell-enhancing activity using spleen cells.
Cytotoxicities of spleen cells incubated with and without heated
proteinase K alone were 9.3 ± 0.8% and 8.2 ± 0.9%, respectively. The
data are means ± SEM of 3 independent experiments.
Properties of an active substance with a NK cell-enhancing activity in
EPOE50. (A) Gel filtration profile of the NK cell-enhancing activity.
Two milliliters of EPOE50 (20 mg/mL) was applied to a Sephadex G-25
column, and 1-mL fractions were collected. Aliquots (50 µL) of each
fraction were subjected to the assay of NK cell-enhancing activity using
spleen cells. Molecular weight markers used were insulin A chain (2531),
bacitracin (1423), and NaCl (58.4). The data are representative of 3
independent experiments with similar results and expressed as means ±
SEM of triplicate cultures. (B) Inactivation of the NK cell-enhancing
activity in EPOE50 treated with periodate. After being incubated with or
without periodate and subsequent removal of periodate by gel filtration
of the reaction mixture, aliquots (50 µL) of each eluted fraction were
subjected to the assay of NK cell-enhancing activity using spleen cells.
Cytotoxicity of spleen cells alone was 7.1 ± 1.8%. The data are means ±
SEM of 3 independent experiments. **P < .01, and
***P < .001, as compared with the values of
control cultures incubated with the eluates of untreated EPOE50. (C) The
NK cell-enhancing activity in EPOE50 is resistant to proteinase K
treatment. After being incubated with or without proteinase K and
subsequent heating, aliquots (50 µL) of each reaction mixture were
subjected to the assay of NK cell-enhancing activity using spleen cells.
Cytotoxicities of spleen cells incubated with and without heated
proteinase K alone were 9.3 ± 0.8% and 8.2 ± 0.9%, respectively. The
data are means ± SEM of 3 independent experiments.
An Active Substance in EPOE50 Is Different From ODN Containing Unmethylated
Deoxycytidine-Phosphate-Deoxyguanosine Dinucleotides
Since oysters filter a large volume of seawater during their feeding activities,
they frequently accumulate bacteria from their environment, the DNA of which has
a much higher frequency of unmethylated deoxycytidine-phosphate-deoxyguanosine
dinucleotides (CpG motif) than that in vertebrate DNA.[30,31] NK cells in human and
murine lymphocytes respond to and are activated by bacterial DNA and ODNs
containing an unmethylated CpG motif.[32-34] This activation of NK
cells is not observed when the highly purified NK cell preparation is used and
thus is caused indirectly by inducing the secretion of IL-12, type I
interferons, and tumor necrosis factor-α presumably from dendritic cells and macrophages.[32] In order to test the possibility that the active substance(s) in EPOE50
with a molecular weight of about 2000 is an unmethylated CpG motif-containing
oligodeoxynucleotide of bacterial origin, we determined whether or not highly
purified NK cells are activated by EPOE50. As shown in Figure 4, NK cells in splenocytes but not
highly purified NK cells were activated by oligodeoxynucleotide 1585 containing
an unmethylated CpG motif. In contrast, EPOE50 markedly induced activation of
not only NK cells in splenocytes but also highly purified NK cells as did
IL-2.
Figure 4.
Activation of highly purified NK cells by EPOE50 but not by ODN 1585.
Spleen cells and NK cells purified by negative plus positive selection
of spleen cells were incubated for 48 hours with or without 0.5 mg/mL of
EPOE50, 1 µM ODN 1585, 1 µM ODN 1585 control, or 5 ng/mL of IL-2. The NK
cell cytotoxic activity against YAC-1 tumor cells was then determined.
The data are means ± SEM of 3 independent experiments.
***P < .001, as compared with the values of
respective control cultures incubated in the medium alone.
Activation of highly purified NK cells by EPOE50 but not by ODN 1585.
Spleen cells and NK cells purified by negative plus positive selection
of spleen cells were incubated for 48 hours with or without 0.5 mg/mL of
EPOE50, 1 µM ODN 1585, 1 µM ODN 1585 control, or 5 ng/mL of IL-2. The NK
cell cytotoxic activity against YAC-1tumor cells was then determined.
The data are means ± SEM of 3 independent experiments.
***P < .001, as compared with the values of
respective control cultures incubated in the medium alone.
Suppression of In Vivo Tumor Growth by EPOE50
NK cells have well-established roles in the host’s immune defense against a
variety of spontaneous and induced cancer. Since NK cell activity in mice was
augmented by treatment with EPOE50, impaired growth of transplanted tumors in
those animals is expected. We therefore examined the effect of EPOE50 treatment
in vivo on the growth of NK cell-sensitive B16 melanoma in mice, a
well-established and widely used tumor model in which treatment is extremely
difficult. B16 cells were subcutaneously inoculated into the lower backs of
mice, and 3 different doses (100, 200, and 300 mg/kg) of EPOE50 was
intraperitoneally administered to mice once a day for 17 days starting 3 days
before tumor inoculation. Figure 5A shows curves of tumor growth in treated and untreated
mice. Administration of the ethanol precipitate dose-dependently suppressed
tumor growth on day 7 and thereafter. In the experiment, the final body weights
of untreated, 100 mg/kg EPOE50 treated, 200 mg/kg EPOE50 treated, and 300 mg/kg
EPOE50 treated mice were 17.4 ± 0.3 g, 17.3 ± 0.3 g, 16.9 ± 0.3 g, and 16.8 ±
0.2 g, respectively, and the body weight gains of untreated, 100 mg/kg EPOE50
treated, 200 mg/kg EPOE50 treated, 300 mg/kg EPOE50 treated mice were 0.71 ±
0.03 g, 0.64 ± 0.04 g, 0.58 ± 0.03 g, and 0.55 ± 0.05 g, respectively. No
significant difference was observed between untreated mice and mice treated with
either dose of EPOE50 in either body weight parameters except significant
difference between untreated mice and 300 mg/kg EPOE50-treated mice
(P < .05) in the body weight gains. An inhibitory effect
of EPOE50 on tumor growth in mice was also observed after its oral
administration (Figure
5B). On the other hand, the proliferation of B16 tumor cells in vitro
was not inhibited but rather was slightly stimulated by EPOE50 (Figure 5C).
Figure 5.
EPOE50 inhibits growth of B16 melanoma in vivo but not in vitro. (A and
B) EPOE50 or PBS was intraperitoneally (100, 200, and 300 mg/kg, A) or
orally (2 g/kg, B) administered to mice once a day for 17 days starting
3 days before B16 melanoma inoculation. The lengths of major and minor
axes of tumors were measured, and the tumor volumes were calculated from
these measurements. The data are means ± SEM of 9 mice (both PBS and
EPOE50) (A) and 5 mice (both PBS and EPOE50) (B).
a-dDifferent superscript letters on the same day indicate
significant difference (P < .05, P
< .01, or P < .001). *P <
.05, as compared with the values of control mice treated with PBS alone.
(C) EPOE50 does not inhibit the proliferation of melanoma in vitro but
instead promotes its proliferation. B16 melanoma cells were incubated
for 48 hours with or without the indicated doses of EPOE50 and subjected
to the MTT assay. The data are expressed as percentage of the values of
control cultures incubated in the medium alone and are means ± SEM of 3
independent experiments. ***P < .001, as compared
with the values of control cultures incubated in the medium alone.
EPOE50 inhibits growth of B16 melanoma in vivo but not in vitro. (A and
B) EPOE50 or PBS was intraperitoneally (100, 200, and 300 mg/kg, A) or
orally (2 g/kg, B) administered to mice once a day for 17 days starting
3 days before B16 melanoma inoculation. The lengths of major and minor
axes of tumors were measured, and the tumor volumes were calculated from
these measurements. The data are means ± SEM of 9 mice (both PBS and
EPOE50) (A) and 5 mice (both PBS and EPOE50) (B).
a-dDifferent superscript letters on the same day indicate
significant difference (P < .05, P
< .01, or P < .001). *P <
.05, as compared with the values of control mice treated with PBS alone.
(C) EPOE50 does not inhibit the proliferation of melanoma in vitro but
instead promotes its proliferation. B16 melanoma cells were incubated
for 48 hours with or without the indicated doses of EPOE50 and subjected
to the MTT assay. The data are expressed as percentage of the values of
control cultures incubated in the medium alone and are means ± SEM of 3
independent experiments. ***P < .001, as compared
with the values of control cultures incubated in the medium alone.
Discussion
We demonstrated in this study that NK cell cytolytic activity was markedly increased
by in vitro treatment of spleen cells and highly purified NK cells with the 30% to
50% ethanol precipitate of oyster extract EPOE50. Intraperitoneal administration of
EPOE50 to mice also enhanced splenic NK cell activity without a change in splenic NK
cell populations. These results suggest that enhancement of NK cell cytotoxicity
induced by administration of EPOE50 is largely dependent on activation of but not on
proliferation or accumulation of NK cells in the spleen. Since the cytolytic
activity of highly purified NK cells was augmented by EPOE50 (Figure 4), it seems likely that EPOE50
directly, not indirectly, activated NK cells. Augmentation of NK cell activity in
vitro after 48-hour treatment with EPOE50 was greater than that after 24-hour
treatment with the same fraction, suggesting that its enhancing process needs many
hours. This time course was not different from that of IL-2-induced enhancement of
NK cell activity (Figure
1B), which shows a gradual increase as reported previously.[35]Wang et al reported that oligopeptide-rich oyster hydrolysates had antitumor activity
and NK cell-enhancing activity in vivo.[36] The oyster hydrolysates they used were enzymatically produced by proteolysis
of oyster proteins with the use of Bacillus sp. SM98011 protease in
vitro. EPOE50 used in our study was prepared from the extract of untreated oysters
without any enzymatic treatment. Thus, to our knowledge, this is the first report on
the stimulatory effects of an oyster preparation with no enzymatic modification on
NK cell activity. Moreover, an active substance in EPOE50 has the properties of a
sugar-containing oligomer or polymer, which is different from oligopeptides as
discussed below.The NK cell-stimulating activity of EPOE50 was completely inactivated by treatment
with periodate but not with proteinase K. Periodate cleaves bonds between adjacent
carbon atoms that contain hydroxyl groups in carbohydrates, creating 2 aldehyde groups.[29] Proteinase K exhibits broad substrate specificity and thus degrades many
proteins and peptides even in the native state.[37,38] The results of gel filtration
of EPOE50 indicated that the activity was eluted with an apparent molecular weight
of 2000. Therefore, the active substance seems to be a sugar-containing oligomer or
polymer such as an oligosaccharide, polysaccharide, or oligonucleotide but not an
oligopeptide. The in vitro NK cell-stimulating effects of some oligosaccharides,
polysaccharides, and ODNs from plants, fungi, and bacteria have been reported.
Fructooligosaccharides of Asparagus recemosus with a polymerization
degree of 7 to 8, a polysaccharide with a molecular mass of 47 kDa isolated from
Litchi chinensis, polysaccharides from Trametes
hirsuta and Pseudostellaria heterophylla, and ODNs
from bacteria enhanced the cytotoxicity of NK cells.[32,39-42] Nigerooligosaccharides, which
are enzymatically synthesized and mainly composed of nigerosyl maltose and nigerosyl
glucose, had a stimulatory effect on NK cells.[43] Moreover, a synthetic heparin-type oligosaccharide that interacts with the
natural cytotoxicity receptor NKp44, one of the activating receptors of NK, enhanced
anti-NKp44-induced release of interferon-γ from an NKp44-expressing NK-92 cell line,
indicating induction of NKp44-mediated NK activation.[44] To date, however, we know of no report concerning polysaccharides or
oligosaccharides of animal origin with an in vitro NK cell-stimulating activity.Although oysters frequently accumulate seawater bacteria whose DNA has the ability to
activate murine NK cells, the following evidence supports the notion that the active
substance of EPOE50 is different from ODNs containing an unmethylated CpG motif.
First, EPOE50 caused activation of highly purified NK cells, while unmethylated CpG
motif-containing ODN 1585 did not. Second, activity of EPOE50 was sensitive to
periodate treatment that cleaves bonds between hydroxyl group–containing adjacent
carbon atoms in carbohydrates as described above, but the deoxyribose moiety of
unmethylated CpG motif-containing ODNs has no such adjacent carbon atoms containing
hydroxyl groups.The growth of B16 melanoma in vivo was significantly suppressed by treatment with
EPOE50. The following lines of evidence indicate that the antitumor effect of EPOE50
in vivo may be mediated through the activation of NK cells. First, NK cell activity
was enhanced by injection of EPOE50 in vivo (Figure 2A). Both EPOE50-caused NK cell
activation and tumor growth inhibition showed the same dose dependence. Second, B16
melanoma cells are a target cell type of NK cells and are killed by NK
cells.[45,46] Third, EPOE50 did not inhibit but promoted the in vitro
proliferation of B16 melanoma cells. If the active substances with B16
proliferation-promoting activity could be separated from that with NK cell-enhancing
activity, more potent suppression of tumor growth in vivo would be obtained,
although it is not known whether the active substances with each activity are
different or not. An in vivo antitumor effect was observed by not only
intraperitoneal injection but also oral administration of EPOE50.Oysters are cultivated and eaten worldwide and have the advantage of being safe. In
fact, consecutive administration of EPOE50 prepared from oyster extract to mice had
minimal effect on body weight gain. The slight decrease in body weight gains
observed in tumor-bearing mice after 17-day treatment with EPOE50 may reflect a
decrease in tumor volumes rather than body weight loss. A recent study by Cheng et
al has shown that oysters have polysaccharides that enhance antigen-specific T
helper 1 (Th1) immunity in vitro and in vivo.[47] Thus, oysters have components that augment not only innate immunity but also
acquired immunity and are potential immunostimulatory agents for defense against
cancers and viral infection.
Conclusion
Our results showed that the ethanol precipitate of oyster extract augmented NK cell
activity in vitro and in vivo and that its administration to mice inhibited tumor
growth presumably through the activation of NK cells. The results also suggest that
the active substance is a sugar-containing oligomer or polymer and is not of
bacterial origin. Oysters might serve as an immunostimulatory food, and it is
worthwhile to identify the active ingredient(s) of oysters.
Authors: Mikael G V Hanson; Volkan Ozenci; Mattias C V Carlsten; Bengt L Glimelius; Jan-Erik A Frödin; Giuseppe Masucci; Karl-Johan Malmberg; Rolf V R Kiessling Journal: Cancer Immunol Immunother Date: 2006-12-02 Impact factor: 6.968
Authors: G Palmieri; S Morrone; P L Lollini; C De Giovanni; G Nicoletti; P Nanni; L Frati; A Santoni Journal: Scand J Immunol Date: 1992-03 Impact factor: 3.487